AstraZeneca hopes to trial 'blockbuster' products in 2023 that will make over a billion in revenue: CFO
Aradhana Sarin, AstraZeneca's chief financial officer, discusses the company's growth plans and its pipeline of products.
UP NEXT
NOW PLAYING: Video
AstraZeneca hopes to trial 'blockbuster' products in 2023 that will make over a billion in revenue: CFO
CNBC
UP NEXT
-
We pay under $700/month to live in 'micro apartments' in NYC — look inside
CNBC
-
The IRS is getting $80 billion dollars over the next 10 years from Congress — Here's why that's a big deal
-
The Look Ahead: March 31, 2023
-
Russia detains WSJ journalist: White House condemns actions as 'unacceptable'
-
Fox v. Dominion: Judge lets $1.6 billion defamation case go to trial
-
Key inflation figure rises less than expected—Here's what it means for the Fed
-
What's up with Charles Schwab? Stock record worst month since 1987
-
Xylem continues to be a top pick as water quality concerns make headlines, says RBC's Deane Dray
-
Cramer on the market's volatility
-
Lightning Round: 3M has too many litigation risks
-
Cramer's brushing up on the top players on the pet space to gauge their next move
-
Final Trades: Tesla, EOG, Delta Airlines and Occidental
-
Why the Chartmaster sees good odds for a strong April market
-
CNBC Markets Now: March 31, 2023
-
Post-Market Wrap: March 31, 2023
-
Micron dips lower after China announces security crack down on memory chips
